Showing 61 - 80 results of 135,350 for search '(( 0 1 decrease ) OR ( 50 ((((we decrease) OR (a decrease))) OR (mean decrease)) ))', query time: 1.32s Refine Results
  1. 61
  2. 62
  3. 63

    Increased osteoblastic activity and decreased osteoclastogenesis in TgLRAP cells <i>in vitro</i>. by Naoto Haruyama (487384)

    Published 2021
    “…Each column represents the mean ± SD. *p<0.05. WT; wild-type mouse, TgLRAP; LRAP transgenic mouse.…”
  4. 64
  5. 65
  6. 66
  7. 67

    Increased lipid accumulation and decreased klotho expressions in palmitate-treated mouse podocytes. by Jeong Suk Kang (7359572)

    Published 2021
    “…Boxes are enlarged images of representative lipid droplets. magnification 20x; scale bar = 50 μm and 100 μm. (c) Western blot showing the decreased expression of klotho and nephrin proteins by palmitate treatment. …”
  8. 68
  9. 69

    Table_1_Decreased Risk in the Pancreatic Cancer With History of Hay Fever: A Meta-Analysis.doc by Guannan Wang (2209297)

    Published 2020
    “…A history of hay fever was associated with a decreased risk of pancreatic cancer (OR, 0.57; 95% CI, 0.500.64, P < 0.00001) through fixed effect model.…”
  10. 70
  11. 71
  12. 72
  13. 73

    Decreased ISCs and increased goblet cells after intestinal specific loss of MLL1. by Neha Goveas (11790822)

    Published 2021
    “…<p><b>(A)</b> Kaplan-Meier survival curve. Tamoxifen was given by gavage for 6 days to mice with the genotype <i>Mll1</i><sup><i>FC/+; Vil-Cre-ERT2/+</i></sup> (n = 12) and <i>Mll1</i><sup><i>FC/FC; RC/+</i></sup> (n = 18). …”
  14. 74
  15. 75

    Trial profile. by Chanel Avenant (409756)

    Published 2024
    Subjects:
  16. 76
  17. 77
  18. 78
  19. 79

    Image_1_Electroencephalographic Evidence for Individual Neural Inertia in Mice That Decreases With Time.JPEG by Andrzej Z. Wasilczuk (11945885)

    Published 2022
    “…EEG was measured after induction of and emergence from isoflurane administered near the EC<sub>50</sub> dose for loss of righting in genetically inbred mice on a timescale that minimizes pharmacokinetic confounds. …”
  20. 80